High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q3
FY2026Q4
FY2027Q1
181.63M
+7.72%
0.447
-0.67%
150.34M
+8.71%
0.322
-15.3%
160.96M
+10.31%
0.370
+2.78%
Estimates Revision
The market is revising Upward the revenue expectations for Doximity, Inc. (DOCS) for FY2026, with the revenue forecasts being adjusted by 1.76% over the past three months. During the same period, the stock price has changed by -26.00%.
Revenue Estimates for FY2026
Revise Upward
+1.76%
In Past 3 Month
EPS Estimates for FY2026
Revise Upward
+3.5%
In Past 3 Month
Stock Price
Go Down
-26.00%
In Past 3 Month
15 Analyst Rating
Wall Street analysts forecast DOCS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DOCS is 68.46 USD with a low forecast of 55.00 USD and a high forecast of 82.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
6 Hold
2 Sell
Moderate Buy
Current: 51.310
Low
55.00
Averages
68.46
High
82.00
Current: 51.310
Low
55.00
Averages
68.46
High
82.00
Raymond James
Outperform -> Strong Buy
upgrade
$75 -> $65
2025-11-21
Reason
Raymond James
Price Target
$75 -> $65
2025-11-21
upgrade
Outperform -> Strong Buy
Reason
Raymond James upgraded Doximity to Strong Buy from Outperform with a price target of $65, down from $75. The stock's risk/reward is "too compelling to ignore" following the post-earnings selloff, the analyst tells investors in a research note. The firm thinks Doximity's long-term growth visibility is improving. Raymond James says the recent pullback has the shares at a discount to the vertical software group that is "too great to ignore."
BMO Capital
Market Perform
initiated
$55
2025-11-12
Reason
BMO Capital
Price Target
$55
2025-11-12
initiated
Market Perform
Reason
BMO Capital initiated coverage of Doximity with a Market Perform rating and $55 price target. Doximity's strong clinician engagement through its social and workflow platform enhances its appeal as a marketing tool for pharmaceutical companies, the analyst tells investors in a research note. While growth opportunities remain through user expansion and monetization, the current valuation suggests much of this potential is already reflected in the share price, BMO says.
Canaccord
Hold
downgrade
$67 -> $58
2025-11-10
Reason
Canaccord
Price Target
$67 -> $58
2025-11-10
downgrade
Hold
Reason
Canaccord lowered the firm's price target on Doximity to $58 from $67 and keeps a Hold rating on the shares. The firm said they posted a strong beat and the previously implied 2H FY'26 guidance was essentially maintained which seemed to drive the shares lower. Canaccord said the conservative stance comes from potential DTC advertising and drug pricing changes that have the possibility to drive Pharma management to alter budgets in remaining months of calendar 2025 and plans for calendar 2026.
Mizuho
Neutral
maintain
$60 -> $62
2025-11-10
Reason
Mizuho
Price Target
$60 -> $62
2025-11-10
maintain
Neutral
Reason
Mizuho raised the firm's price target on Doximity to $62 from $60 and keeps a Neutral rating on the shares. The firm upped estimates post the earnings report citing revenue and margin strength.
Evercore ISI
Elizabeth Anderson
Outperform
downgrade
$81 -> $70
2025-11-07
Reason
Evercore ISI
Elizabeth Anderson
Price Target
$81 -> $70
2025-11-07
downgrade
Outperform
Reason
Evercore ISI analyst Elizabeth Anderson lowered the firm's price target on Doximity to $70 from $81 and keeps an Outperform rating on the shares. The company reported a "strong" Q2, but pull-forward tempers second half growth, the analyst tells investors.
Morgan Stanley
Craig Hettenbach
Equal-weight
maintain
$62
2025-11-03
Reason
Morgan Stanley
Craig Hettenbach
Price Target
$62
2025-11-03
maintain
Equal-weight
Reason
Morgan Stanley analyst Craig Hettenbach says the firm's latest checks point to better-than-expected growth in calendar Q3 and positive sentiment toward a calendar Q4 budget flush, with Doximity's video modules the driving force behind a reacceleration in its growth, consistent with prior checks. The firm, which adds that it finds "no impact" and no overlap with OpenEvidence to date, has an Equal-weight rating and $62 price target on Doximity shares.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Doximity Inc (DOCS.N) is 32.44, compared to its 5-year average forward P/E of 57.22. For a more detailed relative valuation and DCF analysis to assess Doximity Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Fair
5Y Average PE
57.22
Current PE
32.44
Overvalued PE
103.71
Undervalued PE
10.73
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
37.76
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
67.03
Undervalued EV/EBITDA
8.50
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
17.52
Current PS
0.00
Overvalued PS
26.71
Undervalued PS
8.34
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
DOCS News & Events
Events Timeline
(ET)
2025-11-06
16:14:32
Doximity reports Q3 revenue between $180M and $181M, slightly below consensus of $180.7M
2025-11-06
16:13:53
Doximity Announces Q2 Earnings Per Share of 45 Cents, Exceeding Consensus Estimate of 38 Cents
2025-11-06
14:27:07
Prominent Companies Set to Report After Market Close
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/fd0b9d3c488b08c9b7913f2b831c6051fa91159cd412bba2c90fb4ea060af636.png)
Preview
4.0
11-23Yahoo FinanceDoes Raymond James' AI-Centric Upgrade Necessitate a Response from Doximity (DOCS) Investors?
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/de5ddcda178897f960cacd21b787f154f0a57bccb416a34bd01829219206b6a5.png)
Preview
4.0
11-21CNBCRaymond James recommends purchasing this digital health stock as it is 'too compelling to overlook'.
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/414108ce0a84f3e53678d4967552456bb59ff710afea9f3743db362a959b11de.png)
Preview
9.5
11-13BenzingaJim Cramer Advises Against Purchasing This Health Care Stock for Now, Calling It 'Still Overpriced'
Sign Up For More News
People Also Watch
FAQ
What is Doximity Inc (DOCS) stock price today?
What is Doximity Inc (DOCS)'s business?
What is the price predicton of DOCS Stock?
What is Doximity Inc (DOCS)'s revenue for the last quarter?
What is Doximity Inc (DOCS)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Doximity Inc (DOCS)'s fundamentals?
How many employees does Doximity Inc (DOCS). have?